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In spina biﬁda the neural tube fails to close during the embryonic period and it is thought that prolonged
exposure of the unprotected spinal cord to the amniotic ﬂuid during pregnancy causes additional neural
damage. Intra-uterine repair might protect the neural tissue from exposure to amniotic ﬂuid and might
reduce additional neural damage. Biodegradable collagen scaffolds may be useful in case of fetal therapy
for spina biﬁda, but biochemical properties need to be studied. The aim of this study was to investigate
whether biodegradable collagen scaffolds can be used to treat full-thickness fetal skin defects.
We hypothesized that the pro-angiogenic growth factors VEGF and FGF2 would enhance vascularization,
epidermialization and lead to improved wound healing. To investigate the effect of these two growth
factors, a fetal sheep model for skin defects was used. Compared to wounds treated with bare collagen
scaffolds, wounds treated with growth factor-loaded scaffolds showed excessive formation of capillaries
and less myoﬁbroblasts were present in these wounds, leading to less contraction. This study has
demonstrated that collagen scaffolds can be used to treat fetal skin defects and that the combination of
collagen scaffolds with VEGF and FGF2 had a beneﬁcial effect on wound healing.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
There are different congenital structural anomalies in which
closure of skin and underlying structures does not occur during
embryonic development. In spina biﬁda (incidence rate 1 of every
2000 live births) the neural tube fails to close during the embryonic
period and it is thought that exposure of the neural tube to the
amniotic ﬂuid during pregnancy causes additional neural damage
(second hit hypothesis) [1]. Current treatment of spina biﬁda
consists of surgical closureof thedefect in the earlypostnatal period,
in order to prevent infection and further damage. However, the
damage caused by the exposure to the amniotic ﬂuid is irreversible.þ31 50 3619911.
sper).
ll rights reserved.It is expected that intra-uterine repair of the defect diminishes
the damage caused by exposure to amniotic ﬂuid. An additional
advantage of such a fetal intervention is that fetal tissue can
regenerate, instead of repair with ﬁbrosis [2]. During the ﬁrst and
second trimester of development, fetal skin wounds heal with
a normal epidermal and dermal architecture. During the third
trimester a transition from scarless repair to ﬁbrotic repair occurs,
which is comparable to adult wound healing with more inﬂam-
mation and ﬁbrosis [2]. However, the ability of the fetus to heal
full-thickness wounds without ﬁbrosis depends on the size of the
defect, independent of the gestational age [3].
The aim of this study was to investigate whether biodegradable
collagen scaffolds can be used to treat full-thickness fetal skin
defects to allow in situ fetal dermal repair and epidermal over-
growth. For this purpose we developed a fetal skin defect model in
sheep, and treated the defects with a cross-linked type I collagen
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model [4–7]). Collagen scaffolds can bemodulated in different ways
to enhance and regulate wound healing. The porous matrix struc-
ture can be varied and growth factors can be incorporated to
promote angiogenesis and cellular ingrowth. In this study we used
a collagen scaffold and a collagen scaffold loaded with heparin and
two growth factors: vascular endothelial growth factor (VEGF) and
basic ﬁbroblast growth factor (FGF2). Heparin was used for optimal
growth factor binding. VEGF is a 40–45-kDa homodimeric glyco-
protein promoting angiogenesis [8]. FGF2 can also act as angiogenic
factor by directing endothelial cell migration and proliferation. The
combination of VEGF and FGF2 has been reported to have potent
synergistic effects on neovascularization both in in vitro and in vivo
experiments [9–12]. Furthermore, FGF2 reduces scar formation
when exogenously applied to the wound site [13] and diminishes
wound contraction, when used in combination with a collagen
matrix [14]. FGF2 can also act as a potent mitogen for ﬁbroblasts
and keratinocytes [15,16], indicating an effect on both dermal as
well as epidermal healing. With the stimulation of vascular
ingrowth and cellular inﬁltration, regeneration of tissue can be
improved by supplying sufﬁcient oxygen and nutrients. By regu-
lating the host response to the scaffold in this way, formation of
excess scar formation may be prevented.
We evaluated fetal wound healing and closure of full-thickness
skin wounds by means of intra-uterine tissue engineering using
type I collagen scaffolds (COL) and heparinised type I collagen
scaffolds loaded with VEGF and FGF2 (COL-HEP/VF), and compared
these with untreated defects 2, 4 and 8 weeks after fetal surgery.
Cellular ingrowth, vascularization, scar tissue formation and
degradation of the scaffolds were evaluated by histology and
immunohistochemistry.
2. Materials and methods
The study has been approved by the local Ethics Committee on Animal Research
of the Radboud University Nijmegen, The Netherlands (RU-DEC 2007-239).
2.1. Preparation of collagen scaffolds
Type I collagenwas puriﬁed from bovine achilles tendon as described previously
[17,18]. To prepare collagen scaffolds, a 0.67% (w/v) type I collagen suspension in
0.25 M acetic acid was shaken overnight at 4 C and homogenized on ice using
a Potter–Elvehjem homogenizer (Louwers Glass and Ceramic Technologies, Hapert,
The Netherlands). Air bubbles were removed by centrifugation at 100g for 15 min at
4 C. The suspension was then poured into 6-well plates (4 mL per well), frozen at
20 C, and lyophilized. Scaffolds were pre-incubated with 50 mM 2-morpholino-
ethane sulfonic acid (MES) pH 5.0 containing 40% ethanol for 30 min at 22 C. After
removal of this solution, scaffolds were cross-linked using 33 mM 1-ethyl-3-(3-
dimethyl aminopropyl) carbodiimide (EDC) and 6 mM N-hydroxysuccinimide (NHS)
in 50 mM MES pH 5.0 containing 40% ethanol for 4 h at 22 C in the presence or
absence of 0.25% heparin (Diosynth, Oss, The Netherlands). Scaffolds were then
washed, frozen and lyophilized. Scaffolds were disinfected in 70% ethanol (6  7 mL
per well) followed bywashings with sterile PBS (8 7mL per well). The cross-linked
type I collagen scaffold is abbreviated in the text as COL.
The growth factors vascular endothelial growth factor 165 (VEGF; human
recombinant, R&D Systems, Minneapolis, MN, USA) and basic ﬁbroblast growth
factor 2 (FGF2; human recombinant, R&D Systems) were loaded onto the heparin-
cross-linked collagen scaffolds by incubating six Ø 12 mm scaffolds in 5 mL PBS
containing 3.5 mg/mL VEGF and 3.5 mg/mL FGF2, followed by 3 washings with the
same volume of PBS. This scaffold is abbreviated in the text as COL-HEP/VF.
2.2. Analysis of collagen scaffolds
The ultrastructure of the scaffolds was visualized by scanning electron micros-
copy (SEM). Specimens were mounted on stubs, sputtered with an ultrathin layer of
gold in a Polaron E5100 coating system and visualized with a JEOL JSM-6310 SEM
apparatus operating at 15 kV.
The degree of cross-linking of the scaffolds was determined spectrophotomet-
rically by determining the amine group content using 2,4,6-trinitrobenzene sulfonic
acid. Cross-linking efﬁciency was expressed as the percentage of the total number of
amine groups that were used in the cross-linking process [19,20].The heparin content of the ﬁlms was determined applying a hexosamine assay
using p-dimethylamino-benzaldehyde, taking heparin as a standard [21,22].
The amount of growth factors bound to the scaffolds was determined with
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 15%
(w/v) gel, followed by silver staining using a 0.1% (w/v) AgNO3 solution. COL-HEP
scaffolds incubated with growth factors and a standard curve of 0–100 ng of
either VEGF of FGF2 were incubated for 15 min in a boiling water bath under
reducing conditions using 5% (v/v) 2-mercaptoethanol. The intensity of the bands
was analyzed using Adobe Photoshop.
The location of growth factors in the scaffolds was visualized by immunohis-
tochemistry using the ABC method [23] with antibodies HS4C3 [24], goat-anti-
human VEGF (Sigma Chemical Co., St Louis, MO, USA) and rabbit-anti-bovine FGF2
(R&D Systems, Minneapolis, MN, USA).
2.3. Animals and surgical procedures
Nine pregnant ewes of Dutch Texel breed underwent surgery at 79 days’
gestation (term, 140–147 days). For sedation, the animals were pre-medicated with
an intramuscular injection of midazolam (0.5 mg/kg). Anesthesia for surgery was
induced by an intravenous injection of propofol (5 mg/kg) followed by tracheal
intubation. The ewes were maintained on general anesthesia with 1.5% isoﬂurane.
For analgesia, ﬂunixin (2 mg/kg) and sufentanil (4 mg/kg) were given intravenously
followed by a maintenance dosage sufentanil of 2 mg/kg/h. Heart rate, temperature,
oxygen saturation and carbon dioxide concentration of the expired air were moni-
tored. Fetal anesthesia was achieved by transplacental passage of the medications,
administered to the ewe. The abdomen was shaved, cleaned and aseptically
prepared. After a low midline laparotomy under sterile conditions, the uterus was
inspected for the number of fetuses. One uterus horn was exteriorized, wrapped in
gauzes soaked with warm phosphate buffered saline (PBS), and the position of the
fetal lamb was determined by palpation. At a favorable location over the caudal side
of the fetus a hysterotomy was made.
Three circular skin lesions, 12 mm in diameter, were made on the back of the
fetus by excising the skin. The lesion on the left side was covered with a collagen
scaffold (COL). The lesion on the right side was covered with the collagen–heparin
scaffold with VEGF and FGF2 (COL-HEP/VF). The applied scaffolds were slightly
thicker than the removed skin. The lesion in the middle of the back remained
uncovered. The scaffolds were secured and marked with four 6-0 prolene (Ethicon,
Somerville, NJ, USA) interrupted sutures around the skin lesion. After surgery the
fetus was replaced in the uterus and the amniotic ﬂuid volume was restored with
warm PBS solution. Amoxicillin (250mg)was added to the amniotic ﬂuid. The uterus
was closedwith a running suture in 2 layers using 2-0 vicryl (Ethicon, Somerville, NJ,
USA). In case of twin pregnancy the same procedure was performed using the
techniques as described above. Sodium penicillin (1,000,000 IU) was administered
to the intra-abdominal space and the abdominal wall was closed in 3 layers using
EP6 Seraﬁl for the fascia, 2-0 Vicryl for the subcutaneous tissue and 1-0 Vicryl Plus
for the skin. Depomycin (20,000 IU penicillin ml1, 200 mg streptomycin ml1) was
initiated preoperatively (0.6 ml/10 kg) and maintained postoperatively (1 ml/10 kg)
for 3 days via intramuscular injections. Buprenorphine (10 mg/kg, intravenous) and
ﬂunixin (2 mg/kg, intramuscular) were given for three days to provide postoperative
analgesia. The ewes returned to the farm soon after they were able to stand.
2.4. Macroscopic evaluation
The animals were sacriﬁced at three time points. Evaluation took place at 93
days’ gestation (2 weeks post surgery), 107 days’ gestation (4 weeks post surgery)
and 140 days’ gestation (term) in group 1, 2 and 3 respectively. Ewes and fetal
lambs were euthanized by 10 mL intravenously and 5 mL intracardiacally injected
T61 (200 mg embutramide ml1, 50 mg mebezoniumjodide ml1 and 5 mg
tetracainhydrochloride ml1; Intervet, Boxmeer, The Netherlands).
After macroscopic evaluation and photography of the wound, the size of the
defect wasmeasured between themarking sutures andwas used to calculate wound
contraction. Wound contraction was expressed as the percentage of the size of the
defect at time of evaluation against the original size of the defect of 12mm at time of
surgery. All data are represented as mean  SEM. The data were analyzed using
computer statistical software (GraphPad Prism, GraphPad Software Inc.). The
statistic signiﬁcance of differences in the ﬁndings was evaluated by a one-way
ANOVA followed by post hoc Bonferroni analysis. A difference was considered
statistically signiﬁcant when p < 0.05.
2.5. Histological techniques
Samples of the skin and subcutaneous tissue were taken at the level of the skin
lesions, ﬁxed in 4% (v/v) buffered formaldehyde and parafﬁn-embedded for histo-
logical analysis or snap-frozen and stored at 80 C. Serial cross-sections were cut
(4 mm) and stained with haematoxylin and eosin, toluidine blue and Masson’s
trichrome. Additionally, immunohistochemical stainings for a-smooth muscle actin
(a-SMA), pancytokeratin and type IV collagen were performed on parafﬁn-
embedded sections. The sections were deparafﬁnized and washed with PBS.
Endogenous peroxidases were blocked with 3% (v/v) H2O2/PBS for 30 min at room
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Sodium Citrate, pH 6.0) during 10 minwas performed for sections stained for a-SMA
and cytokeratin. Sections stained with anti-type IV collagen were treated with 0.1%
(v/v) protease (Sigma–Aldrich, St. Louis, MO, USA) for 30 min at room temperature
for antigen retrieval. Slides were pre-incubated with 5% serum from the species that
produced the secondary antibody.
a-SMA was detected with mouse a-SMA (1:15.000, clone 1A4; Sigma–Aldrich)
and peroxidase-conjugated goat-anti-mouse antibody (1:200; SBA, Birmingham,
USA, cat.no.1080-05). Immunostaining of cytokeratin was performed by overnight
incubation at 4 C of mouse-anti-cytokeratin (1:800, clone AE1/AE3; Labvision
corporation, Fremont, USA), followed by biotinylated horse-anti-mouse and
peroxidase-conjugated ABC complex (Vector Laboratories, Burlingame, USA). Type
IV collagen was detected using rabbit anti-type IV collagen (1:100; Abcam,
Cambridge, UK), biotinylated goat-anti-rabbit (Dako) and peroxidase–conjugated
streptavidine (Dako). Color development was performed with power DAB (a-SMA
and cytokeratin, Immunologic, Duiven, The Netherlands,) and 3-amino-9-ethyl-
carbazole (type IV collagen, Sigma, Steinheim, Germany). Sections were counter-
stained with Mayer’s haematoxylin (Fluka Chemie, Buchs, Switzerland).3. Results
3.1. Scaffolds
Scanning electron microscopy revealed a porous scaffold with
a rather open top side and a more closed pan side (Fig. 1A). Cross-
linking efﬁciency was 31  8% for COL scaffolds and 31  4% for
heparinised COL scaffolds (mean  SD). To heparinised COL scaf-
folds, 13.1  2.4% heparin was bound (mean  SD). Heparin was
bound evenly throughout the scaffold. The amount of growthFig. 1. Scanning electron microscopical images of collagen scaffolds cross-linked in the absen
view and cross-section. The more closed pan side was implanted such that it was in contact w
VF scaffolds (B). Note that heparin and FGF2 were evenly distributed through the scaffold,factors bound per mg heparinised COL scaffold was 0.26  0.05 mg
for VEGF and 0.10  0.04 mg (mean  SD) for FGF2. FGF2 was
present throughout the scaffold whereas VEGF was mainly present
at the edges of the scaffold (Fig. 1B).
3.2. Animal surgery
Eight ewes and 13 fetal lambs underwent surgery (6 ewes were
bearing twins). The overall fetal survival rate was 85% during the
pregnancy period. In one sheep, twin pregnancy could not be
determined at time of surgery and only one fetus was operated.
One sheep aborted 2 days after the surgery probably due to severe
enteritis of the ewe and needed to be sacriﬁced accounting for the
only maternal death in the study. At autopsy, herniation of
a bowel loop between the fascial sutures was found. In one sheep,
a thermal intestinal lesion occurred during the surgery which was
repaired. All other procedures went uneventful. Eleven lambs
were evaluated; four in group 1 (93 days), three in group 2 (107
days) and four in group 3 (140 days). The survival rate was similar
to previously published data for fetal surgery on similarly aged
fetal lambs [5–7].
3.3. Macroscopic evaluation
A macroscopic overview with examples of wound healing is
depicted in Fig. 2A. On macroscopic inspection, the skin defectsce (top row) or presence of heparin (bottom row) (A). Shown are the top view, bottom
ith the amniotic ﬂuid. Immunolocalisation of heparin, VEGF and FGF2 in the COL-HEP/











































Fig. 2. Macroscopical overview of wound healing after surgery at 93 days’ (2 weeks post surgery), 107 days’ (4 weeks post surgery) and 140 days’ gestation (term) (A). Note the
shape of contraction of the untreated lesion and the reddish appearance of the wound treated with COL-HEP/VF. Percentage of wound contraction (B). At 2 and 4 weeks post surgery
less contraction was present in COL treated wounds compared to untreated wounds. At all time points less contraction was present in COL-HEP/VF treated wounds compared to
untreated wounds. * signiﬁcant difference between untreated and COL or COL-HEP/VF (p < 0.05). # signiﬁcant difference between COL and COL-HEP/VF treated (p < 0.05).
N.A. Hosper et al. / Biomaterials 31 (2010) 3910–3919 3913were visible in all groups. The untreated defects were completely
closed at 8 weeks post surgery, with thewound edges contracted to
each other. COL treated wounds showed remnants of the scaffold at
2 and 4 weeks post surgery, at term (8 weeks post surgery) the
wound was completely closed without visible remnants of the
scaffold. A reddish appearance of the remnants of the COL-HEP/VF
treated wounds was present at 2 weeks, suggesting angiogenesis.In contrast to COL treated wounds, COL-HEP/VF treated wounds
showed remnants of the scaffold at term.
The percentage of wound contraction of the treated and
untreated defects is shown in Fig. 2B. At 2 weeks, the percentage of
wound contraction of the COL treated defects was decreased and
this was more obvious when using a COL-HEP/VF scaffold. At 4 and
8 weeks, contraction was also found in the COL treated defects but
N.A. Hosper et al. / Biomaterials 31 (2010) 3910–39193914again the contraction of the COL-HEP/VF scaffold was less (w30%).
At term, the degree of wound contraction of the uncovered group
was almost 80%.
3.4. Microscopic evaluation
Two weeks after surgery (93 days’ gestation), the untreated
wounds were covered by a ﬁbrin clot. The newly formed epidermis
fullyclosed thewoundarea and separated thegranulation tissue from
the clot; the epidermal cells hadmigrated over the interface betweenFig. 3. Masson’s trichrome staining of skin defects at different time points. Untreated defect
weeks (E) and 8 weeks (H). Defect treated with COL-HEP/VF at 2 weeks (C), 4 weeks (F) and
indicates the border between surrounding tissue and the scaffold. E ¼ epidermis, D ¼ dermis
images. Original magniﬁcations: 50 (A–I) and 200 (A1–I1).the clot and the developing granulation tissue. The newly formed
epidermis was, at this time point, less than twice as thick as the
normal epidermis distal from the wound area (Fig. 3A); the overall
thickness was very regular (Fig. 4A). The granulation tissue consisted
of a more open extracellular matrix (ECM) network compared to the
normal dermis and was populated by numerous cells (Fig. 3A2). The
latter appeared to be mainly myoﬁbroblasts as based on their
morphology and conﬁrmedby a-SMA staining (Fig. 5A). Compared to
the normal fetal dermis in development, less mature blood vessels
and capillaries were present in the wounded area (Fig. 3A).at 2 weeks (A), 4 weeks (D) and 8 weeks (G). Defect treated with COL at 2 weeks (B), 4
8 weeks (I). The black striped line indicates the edge of the defect; the black dotted line
, S ¼ scaffold. The boxed areas denote the corresponding region of higher magniﬁcation
Fig. 4. Epithelialization. Cytokeratin staining of skin defects at different time points. Untreated defect at 2 weeks (A), 4 weeks (D) and 8 weeks (G). Defect treated with COL at 2
weeks (B), 4 weeks (E) and 8 weeks (H). Defect treated with COL-HEP/VF at 2 weeks (C), 4 weeks (F) and 8 weeks (I). Original magniﬁcations: 50 (A–I).
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covering the top of the scaffold (not shown). Interestingly, the
epidermis grew from both sides through the upper part of
the scaffold, but did not completely close at this time point. TheFig. 5. Myoﬁbroblasts. SMA staining of skin defects at different time points. Untreated defec
weeks (E) and 8 weeks (H). Defect treated with COL-HEP/VF at 2 weeks (C), 4 weeks (F) anthickness and shape of the newly formed epidermis was rather
irregular (Figs. 3B and 4B) and was generally thicker than the
epidermis of the untreated wound (i.e. the wound without a scaf-
fold). New ECM formation occurred at the interface between thet at 2 weeks (A), 4 weeks (D) and 8 weeks (G). Defect treated with COL at 2 weeks (B), 4
d 8 weeks (I). Original magniﬁcations: 50 (A–I).
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was observed at the dermal side of the scaffold (Fig. 3B2). Inﬁltra-
tion of cells, mainly a-SMA positive (Fig. 5B), was seen in the
scaffold. In the scaffold only a few small blood vessels were formed
(Fig. 3B).
The wounds treated with the COL-HEP/VF scaffold also showed
a ﬁbrinous clot on top of the scaffold. Here again, the epidermis
grew from both sides through the upper part of the scaffold.
However, the newly formed epidermis was much more hyper-
plastic (Fig. 3C versus B; Fig. 4C versus B) with a highly irregular
shape. The wound area was also not completely covered by the
epidermis. Less ECM formation was seen at the interface between
the scaffold and the epidermis compared to thewound treatedwith
the bare COL implant (Fig. 3C1 versus B1; Fig. 3C2 versus B2) and
fewer a-SMA-positive cells inﬁltrated into the scaffold (Fig. 5C
versus B). A few small blood vessels were present in the scaffold
(Fig. 3C), which was comparable to the amount in the COL treated
wound at this time point.
Four weeks after surgery (107 days’ gestation), the clot of the
untreated wounds was not longer present and the thickness of the
newly formed epidermis was completely normalized (Figs. 3D and
4D). A more dense ECM network was formed. A general decrease in
cell number was seen (Fig. 3D1 and D2 versus A2); myoﬁbroblasts
were only sporadically seen (Fig. 5D). At this time point more small
as well as mature blood vessels were observed at the dermal side of
the newly formed tissue (Fig. 3D2) compared to two weeks,
however less blood vessels than in the normal fetal dermis.
In the wounds treated with COL, the clot was still present
(Fig. 3E). The thickness of the newly formed epidermal layer was
not normalized (Fig. 4E), but the wound area was completely
covered by the epidermis at this time point. Single cells were
present between the collagen bundles of the entire scaffold
(Fig. 3E2) and numbers of a-SMA-positive cells were even
decreased compared to the earlier time point (Fig. 5E versus B).
Most importantly, a newly formed ECM layer was present between
the epidermis (Fig. 3E and E1) and the scaffold which was devoid of
myoﬁbroblasts (Fig. 5E) and in which several blood vessels were
formed, comparable to the appearance of the normal dermis. Only
a few mature blood vessels were formed in the scaffold as revealed
by a collagen IV staining (Fig. 6A).
In the wounds treated with COL-HEP/VF the clot was also still
present. The newly formed epidermis was still hypertrophic with
an irregular shape (Fig. 4F). ECM formation was mostly observed at
the epidermal side of the scaffold (Fig. 3F1) and contained
a decreased amount of myoﬁbroblasts (Fig. 5F) compared to the
earlier time point. In the scaffold further distal of the epidermis
hardly any ECM formation was seen (Fig. 3F2). Compared to the
bare COL implant, less cells, mainly a-SMA-negative (Fig. 5F), were
present in the scaffold (Fig. 3F2 versus E2), but a similar amount of
blood vessels was present in the scaffold (Fig. 6B versus A).
Eight weeks after surgery (140 days’ gestation), the untreated
wound had completely lost its clot. The granulation tissue was
entirely replaced by ECM and had a density comparable with the
normal dermis (Fig. 3G). There were no skin appendages in the
newly formed tissue (Fig. 4G) and myoﬁbroblasts were absent
(Fig. 5G). A comparable amount of mature blood vessels was
present in this newly formed ECM (Fig. 3G) when compared to the
normal fetal dermis.
In the wounds treated with COL, the clot was also lost, whereas
still parts of the epidermis were thickened (Fig. 3H). Interestingly,
the entire scaffold was degraded and replaced by ECM (Fig. 3H).
A decreased amount of myoﬁbroblasts was seen compared to four
weeks (Fig. 5E versus H). A higher amount of blood vessels was
present throughout the newly formed ECM layer (Figs. 3H1, H2 and
6C) compared to the normal dermis.In contrast, in the wounds treated with COL-HEP/VF part of the
clot was still present. The thickness of the epidermal layer had
decreased (Figs. 3I and 4I), but was still thicker than the newly
formed epidermis of the untreated and the COL treated wound.
Remarkably, some of the skin appendages of the epidermis were
formed in the newly formed ECM (Figs. 3I1 and 4I). This ECM layer
was not as dense as the newly formed ECM in the untreated and the
COL treated wound. In contrast to the latter, a considerable part of
the scaffold was still present (Fig. 3I). Although it still concerned
low numbers, a higher inﬂux of cells was seen in the scaffold at this
time point compared to four weeks after treatment (Fig. 3I2 versus
F2). The amount of myoﬁbroblasts was decreased compared to the
four week time point (Fig. 5I versus F). Besides mature blood
vessels, many capillaries were formed in the scaffold (Fig. 6D and
D1).
4. Discussion
Fetal tissue engineering has been proposed as a new concept in
the surgical reconstruction of birth defects in the fetal period [25].
However, despite being a promising concept, hardly any studies
have been published to tackle the various steps needed to establish
a proof-of-concept. In this study we investigated whether biode-
gradable scaffolds with or without growth factors can be used to
treat full-thickness fetal skin defects which facilitate epidermal
overgrowth and dermal repair. We studied the healing of these skin
defects by use of a bare collagen type I (COL) scaffold, a heparinised
COL scaffold loaded with VEGF and FGF2 (COL-HEP/VF), or left
untreated (no scaffold). We hypothesized that the pro-angiogenic
growth factors VEGF and FGF2 might enhance vascularization and
epithelialization, leading to improved wound healing.
The study showed that at term (8 weeks post surgery) proper
epidermal layers were formed in all defects. Less wound contrac-
tion occurred in COL treated defects compared to untreated defects.
Even less contraction was present in defects treated with COL-HEP/
VF, but in contrast to COL treated defects, degradation of the
scaffold was not completed at term. Concerning degradation of the
scaffold, hardly or no macrophages inﬁltrated the COL and
COL-HEP/VF scaffolds, suggesting that these cells did not play a role
in fetal tissue engineering. Similar amounts or even less blood
vessels were formed in the defects compared to the developing
fetal dermis, with exception of COL-HEP/VF treated defects at term,
showing excessive formation of capillaries in the scaffold. Overall,
myoﬁbroblasts were involved in the remodeling of the tissue, i.e.
ECM formation and wound contraction.
It is highly important that wound contraction and scar forma-
tion will be minimized after fetal skin defects, as the fetus grows
rapidly. Therefore we investigated the formation of ECM and the
amount of contraction in time. Previously, a fetal sheep model has
shown that the transition period from scarless to healing with scar
formation in sheep occurs between 100 and 120 days [3]. However,
fetal skin repair is not only dependant on gestational age, but also
on the size of the defect. Wounds in mid-gestation fetal lambs of
2–4 mm heal without scarring, whereas wounds of 6–10 mm heal
with formation of a scar [3]. In our study, wounds of 12 mm were
made at 79 days of gestation. It was expected that the untreated
wounds would heal with scar formation due to the size of the
wound. Indeed, all untreated defects showed healing with scar
formation and contraction. However, clearly less wound contrac-
tion was observed with COL treatment. Myoﬁbroblasts have
contractile characteristics in an attempt to close the wound.
Another function of myoﬁbroblasts is the production of new ECM
components. A comparable amount of myoﬁbroblasts was seen at
two weeks post surgery in untreated and COL treated wounds. At 4
and 8 weeks myoﬁbroblasts were still present in COL treated
Fig. 6. Vascularization. Collagen IV staining of skin defects at different time points. Defect treated with COL at 4 weeks (A) and 8 weeks (C). Defect treated with COL-HEP/VF at 4
weeks (B) and 8 weeks (D). The boxed areas denote the corresponding region of higher magniﬁcation images. Original magniﬁcations: 50 (A–E) and 200 (A1–E1).
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hypothesized, treatment of the skin defect with COL-HEP/VF
diminished contraction even more. In accordance with this, fewer
myoﬁbroblasts were present. This is probably due to the incorpo-
ration of FGF2, because in vitro and in vivo studies have shown that
FGF2 can inhibit and reverse the differentiation of ﬁbroblasts to
myoﬁbroblasts [13,14,26,27].
Implantation of a biomaterial, like our degradable type I
collagen scaffold, will induce an inﬂammatory response by the
non-speciﬁc immune system, known as the foreign body reaction
(FBR). In general the FBR will induce resorption of degradable
scaffolds after implantation. Key players in the adult FBR are
macrophages and giant cells. However, little is known about the
FBR in fetal applications. It is known that in fetal wound healing less
inﬂammation is induced compared to adult wound healing, which
can be due to the fact that the innate immune system is less maturein the fetus. In the current fetal lamb model hardly any or no
macrophages were detected in any of the histological specimens,
and most of the cells were myoﬁbroblasts. We wanted to conﬁrm
the scarcity of macrophages by a macrophage staining, but anti-
bodies against sheep macrophages are not available. Several other
macrophage antibodies have been tested to see if these cross-react,
but none of these antibodies were successful. In accordance with
the absence of macrophages, also giant cells (fused macrophages)
were not present in the fetal skinwounds. This is a major difference
with the adult situation in which implanted biodegradable
scaffolds are ﬁnally phagocytosed by giant cells. In the current
fetal model, COL and COL-HEP/VF scaffolds did degrade but as
mentioned giant cells were not involved, suggesting that the scaf-
folds were degraded by enzymes secreted by (myo)ﬁbroblasts.
In fetal tissue engineering it is important that a good balance
exists between the degradation of the scaffold and new tissue
N.A. Hosper et al. / Biomaterials 31 (2010) 3910–39193918formation, i.e. epithelial overgrowth and proper dermal regenera-
tion. We observed a faster tissue remodeling in the COL treated
wounds compared to COL-HEP/VF treated defects. At four weeks in
COL treated wounds, part of the collagen scaffold was degraded and
replaced by an ECM layer that integrated with the original dermis.
At eight weeks, the entire scaffold was degraded and replaced by
new ECM. In contrast, in the COL-HEP/VF treated wounds, a large
part of the scaffold was still present at 8 weeks post surgery,
demonstrating that remodeling is still in progress. These differ-
ences between COL and COL-HEP/VF implicate that fetal TE can be
inﬂuenced by growth factors leading to different degradation
patterns.
Another major difference between COL and COL-HEP/VF treated
defects was the hyperplasia of the epidermis observed at 2 and 4
weeks post surgery in COL-HEP/VF treated wounds. This could be
caused by FGF2 as well as VEGF. It is known that FGF2 can have
a mitogenic effect on keratinocytes, thereby promoting epithelial-
ization in adult wound healing [15,16]. VEGF can also stimulate the
proliferation and migration of keratinocytes in vitro [28]. Further-
more, application of VEGF in a diabetic wound healing model
showed accelerated wound healing with enhanced epithelializa-
tion [29]. However, ﬁnally at 8 weeks a proper epidermal layer has
been formed. Furthermore, enhanced angiogenesis was observed in
the COL-HEP/VF treated wounds. Both VEGF and FGF2 can promote
angiogenesis and the combination of VEGF and FGF2 has been
shown to have synergistic effects on neovascularization both
in vitro and in vivo [9–12]. Although excessive formation of capil-
laries was observed in these scaffolds 8 weeks post surgery, we do
not know whether these capillaries are functional, because eryth-
rocytes were not observed in these capillaries.
A highly interesting observation is the formation of new
appendages in the wounded area of the COL-HEP/VF treated
wounds 8 weeks after surgery. Regeneration of these specialized
structures indicates an enhanced functional healing. These newly
formed appendages were less mature (smaller compared to
appendages in the normal skin at this time of development) than
the appendages in the unwounded skin, indicating that the
appendages have not migrated from the wound edges.
For optimal binding of growth factors to the scaffold, the scaf-
folds were heparinised. We have to realize that directly after
implantation the scaffold is in contact with the amniotic ﬂuid. It is
known that several growth factors are present in the amniotic ﬂuid,
like hepatocyte growth factor (HGF), insulin-like growth factor
(IGF), FGF2, and VEGF. We can not exclude that, in addition to the
loaded growth factors, also growth factors from the wound site or
from the amniotic ﬂuid bound to the heparin in COL-HEP/VF,
leading to a long-term effect of these growth factors.
For future tissue engineering approaches of congenital defects
such as spina biﬁda, scaffolds could be useful for wound closure.
In utero coverage of the defect with a scaffold will shorten the
exposure time of the spinal cord to the amniotic ﬂuid, which will
likely improve the neurologic outcome by preventing further
damage. However, future studies will be needed to investigate if
the addition of growth factors is beneﬁcial in the case of spina
biﬁda.
5. Conclusion
The evaluation of biomaterials for speciﬁc applications should
be evaluated in model systems resembling the clinical situation.
This study showed that tissue engineering in utero is a promising
method in treatment of full-thickness fetal skin defects. Both COL
and COL-HEP/VF treated wounds showed a proper re-
epithelialization and healing without a (chronic) FBR. COL treated
wounds show less contraction than untreated wounds and thiseffect was even enhanced in COL-HEP/VF. Furthermore, the addi-
tion of these growth factors leads to an increased angiogenesis and
to regeneration of the skin appendages.Acknowledgements
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